HUA MEDICINE-B (02552) surged over 4% in late trading, closing up 3.55% at HK$3.5 with a turnover of HK$16.7041 million. The company's core product, dorzagliatin, the world's first glucokinase activator (GKA) drug, was approved in 2022. After regaining commercialization rights in 2025, sales accelerated rapidly, with H1 revenue growing 110% YoY and profitability improving due to deferred income from Bayer.

Leveraging its unique drug development mechanism, the company is advancing its second-generation GKA using sustained-release technology and has submitted a clinical application to the FDA, marking its entry into global markets. GKA, as a novel oral anti-diabetic drug, previously faced R&D challenges due to side effects and efficacy concerns. However, recent trends show commercialization of first-generation drugs, international expansion of second-generation products, and deeper safety and efficacy research.

Among Chinese listed companies, HUA MEDICINE-B stands as the industry leader in GKA development, with no other firms having active core GKA pipelines. The company's mid-term report disclosed a real-world study in China involving 80 centers and 2,000 type 2 diabetes patients, further validating dorzagliatin's broad applicability and safety. New findings in diabetes remission and cognitive improvement solidify HUA MEDICINE-B's global leadership in GKA R&D and treatment.